{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-052077","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.343360+00:00","generated_at":"2026-05-16T20:15:22.416687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vistagen reports Q2 FY2026 net loss $19.4M; PALISADE-3 Phase 3 complete, topline due Q4 2025","bullets":["Net loss $19.4M vs $13.0M YoY; R&D expense $15.9M (up 56% YoY) on PALISADE program.","PALISADE-3 Phase 3 trial of fasedienol for social anxiety disorder completed; topline data expected by Q4 2025.","PALISADE-4 Phase 3 trial topline expected H1 2026; same public speaking challenge design.","Cash, equivalents, and marketable securities $77.2M as of Sep 30, 2025.","Paul Edick appointed to board of directors, effective October 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-052077","json":"https://secwatch.observer/filing/0001628280-25-052077.json","markdown":"https://secwatch.observer/filing/0001628280-25-052077.md","text":"https://secwatch.observer/filing/0001628280-25-052077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/0001628280-25-052077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/vtgn-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:15:22.416687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}